Genetically engineered T cells are powerful new medicines, offering hope for curative
responses in patients with cancer. Chimaeric antigen receptors (CARs) are a class of …

Highlights•The CD19 paradigm has established CARs as a novel immunotherapy in
oncology.•The synthetic tool box is not limited to CARs and includes CCRs, iCARs and …

Genetically engineered T cells are powerful new medicines, offering hope for curative
responses in patients with cancer. Chimeric antigen receptor (CAR) T cells were recently …

Chimeric antigen receptors (CARs) are synthetic receptors that reprogram T lymphocytes to
target chosen antigens. The targeting of CD19, a cell surface molecule expressed in the vast …

Spearheaded by the therapeutic use of chimeric antigen receptors (CARs) targeting CD19,
synthetic immunology has entered the clinical arena. CARs are recombinant receptors for …

Chimeric antigen receptor (CAR) T cells have proven that engineered immune cells can
serve as a powerful new class of cancer therapeutics. Clinical experience has helped to …

This year marks the tenth anniversary of cell therapy with chimeric antigen receptor (CAR)-
modified T cells for refractory leukemia. The widespread commercial approval of genetically …

The immune system evolved to distinguish non-self from self to protect the organism. As
cancer is derived from our own cells, immune responses to dysregulated cell growth present …

Chimeric antigen receptor (CAR) T cell therapies have evolved from a research tool to a
concept-shifting therapy with impressive responses in B cell malignancies. This Review …

Engineering stem cells presents an attractive paradigm for cancer immunotherapy. Stem
cells engineered to stably express various chimeric antigen receptors (CARs) or T-cell …